L26/P-892 Limitations in the Measurable Residual Disease (MRD) Detection in Ovarian Tissue from Patients with Acute Leukemia
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von A. Wolfromm und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Study question What are the technical limitations of MRD detection in ovarian tissue from leukemia patients? Summary answer MRD assessment in ovarian tissue is currently limited, mainly due to tissue-specific characteristics that differ substantially from recommended MRD testing in blood and bone marrow. What is known already Survival rates for acute leukemia are improving, and more patients are cured thanks to advances in treatment, including allogeneic hematopoietic stem cell transplantation (HSCT). However, HSCT frequently causes premature ovarian insufficiency in 70–90% of young women. Ovarian tissue cryopreservation (OTC) before gonadotoxic therapy, followed by autotransplantation, can restore fertility. Yet concerns persist about leukemia relapse due to residual leukemic cells in ovarian tissue. MRD assessment remains challenging, and standard hematologic MRD methods are not directly applicable to ovarian samples. As no specific recommendations exist, we aim to define the technical limitations of ovarian MRD assessment in acute leukemia. Study design, size, duration We included 25 patients with AML and 30 patients with ALL who performed ovarian tissue cryopreservation between 1999 and 2025. Residual material (ovarian cortex and medulla) was used to assess MRD based on initial disease characteristics. If no molecular markers were reported at diagnosis, NGS was performed on residual blood samples. Participants/materials, setting, methods After identifying the molecular markers by NGS sequencing using the 52-gene panel the ovarian MRD was evaluated using droplet digital PCR with specifically designed and validated primers. DNA and RNA were extracted either from residual frozen medulla or cortex. At least 2 ovarian tissue samples were analyzed per patient. Cryopreserved ovarian fragments from MRD-positive patients were grafted into six-week-old female NOD-SCID immunodeficient mice, and MRD was assessed five months after grafting. Main results and the role of chance 55 patients underwent ovarian tissue cryopreservation after chemotherapy. A total of 36 patients were excluded from analysis: insufficient tissue material (n = 5), missing information at diagnosis (n = 3), no identified molecular abnormalities (n = 2). For 26 patients, abnormalities were detected but were considered not optimal for MRD monitoring according to ELN-DAVID recommendations (e.g., RUNX1 mutations) or were not suitable for ovarian tissue MRD assessment in ovarian cortex samples. These include the low lymphocyte content, which limits IGH/TCR-based MRD assessment, the overexpression of ABL1 as reference gene, and WT1 in ovarian tissue. 19 patients harbored molecular abnormalities that could potentially be used for MRD assessment in ovarian tissue (medulla and cortex), including CBFB::MYH11 (inv(16)), KMT2A (MLL) rearrangements, BCR/Abl P190 rearrangement, and mutations such as NPM1, FLT3-ITD, KRAS, IDH1/2, and NRAS. Droplet digital PCR (ddPCR) was currently designed and performed in 9 patients using 14 MRD targets. MRD was negative in 5 patients and positive in 4 patients in medulla and/or cortex samples, although 3 of them had received first chemotherapy regimen before OTC. Xenograft have been performed for 3 patients with positive samples but did not showed positivity 5 months after transplantation. Limitations, reasons for caution Almost 50% of the patients (26/55) had abnormalities considered not suitable for ovarian tissue MRD assessment without extensive protocol validation, limiting the final number of patients evaluated and their future clinical use. MRD assessment is ongoing for 10 patients. Wider implications of the findings Our study highlights that MRD assessment in ovarian tissue is limited, mainly due to tissue-specific characteristics that differ from those of blood and bone marrow, for which MRD testing recommendations have been published. These findings underscore the need for ovarian-specific guidelines and further studies to validate appropriate MRD detection techniques. Trial registration number No
Zitieren
APA
Wolfromm, A., Steen, G. V. D., Landtsheer-Pletsa, N. D., Dewispelaere, L., Housni, H. E., & Heimann, P. (2026). L26/P-892 Limitations in the Measurable Residual Disease (MRD) Detection in Ovarian Tissue from Patients with Acute Leukemia. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1216
Vancouver
Wolfromm A, Steen GVD, Landtsheer-Pletsa ND, Dewispelaere L, Housni HE, Heimann P. L26/P-892 Limitations in the Measurable Residual Disease (MRD) Detection in Ovarian Tissue from Patients with Acute Leukemia. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1216
BibTeX
@article{Wolfromm2026,
author = {Wolfromm, A. and Steen, G. Van Den and Landtsheer-Pletsa, N. De and Dewispelaere, L. and Housni, H. El and Heimann, P.},
title = {L26/P-892 Limitations in the Measurable Residual Disease (MRD) Detection in Ovarian Tissue from Patients with Acute Leukemia},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1216}
}
EUVIMED